Teva to Distribute Three Rosetta Genomics Cancer Diagnosis Tests in Israel and Turkey
Posted Jan 11 2009 4:20pm
If you read my interview with Rosetta earlier this week, you will know how important these tests are in diagnosing “cancer of the unknown primary”with lung cancer tumors. In case you missed it, here’s the link below:
Rosetta Genomics– Today I had the opportunity to speak with and interview Ronen Tamir, Chief Commercialization Officer, at Rosetta to find out howmicroRNAis helping diagnose and treat cancer.
miRview™ squamous is a microRNA-based molecular diagnostic test that accurately differentiates squamous from non-squamous non-small cell lung cancer (NSCLC).
miRview™ mets is a microRNA-based molecular diagnostic test that identifies the tissue-of-origin of metastatic tumors.
miRview™ meso is a microRNA-based molecular diagnostic test that differentiates malignant pleural mesothelioma from peripheral adenocarcinomas of the lung or metastatic carcinomas involving the lung pleura.
The tests are making it able to locate the source of cancer for many patients where the diagnosis has never been found and will lead to better coordinated treatment plans for lung cancer. BD
NEW YORK (GenomeWeb News) — Rosetta Genomics has inked an agreement under which Teva Pharmaceutical Industries will distribute three of the company’s microRNA-based molecular diagnostic cancer tests in Israel and Turkey.
Rosetta Genomics Chief Commercialization Officer Ronen Tamir said that because Israel has provided its citizens with health insurance under the National Health Law it is “a very attractive market,” adding that Turkey is “a country with significant market potential.”